• Fine Foods & Pharmaceuticals swung to a net loss of EUR 1.69 million in the first nine months of 2026.
• Revenue fell year over year to EUR 185.6 million, while pharmaceutical revenue climbed 16% to EUR 72.6 million.
• Pharmaceutical growth benefited from the Brembate expansion and Sofar acquisition, with Sofar contributing about EUR 10 million in revenue.
• Net debt more than doubled from December 2025 to EUR 99.9 million, due to the Sofar acquisition and industrial investments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fine Foods & Pharmaceuticals NTM S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20094_173506_2026_oneinfo.pdf), on November 10, 2026, and is solely responsible for the information contained therein.